The field of digital health regulation is in constant flux, a dynamic environment where technological innovation frequently outpaces established legal frameworks. The FDA’s ambitious Digital Health Software Pre-Certification (Pre-Cert) Program, though concluded, is a key case study, illuminating both the agency’s forward-thinking approach and the inherent statutory limitations that shape its ability to regulate agile, software-driven medical technologies. This exploration digs into the broader context of the Pre-Cert pilot, examining how its lessons continue to inform contemporary regulatory policy and underscore the critical need for legislative reform in the age of AI.
The Genesis and Aspirations of the Pre-Cert Pilot
The FDA, through its Digital Health Center of Excellence (DHCoE), launched the Pre-Cert program with a revolutionary aim: to shift regulatory focus from a product-centric model to a firm-based approach. Recognizing the iterative development cycles inherent in software, particularly Software as a Medical Device (SaMD), the agency sought a pathway that would assess the organizational excellence and quality management systems of developers, rather than requiring extensive premarket review for every minor software update. The underlying premise was that if a company consistently demonstrated a culture of quality, clinical responsibility, and strong development practices, its products could potentially undergo a more simplified review process. This innovative model was designed to foster agility and accelerate patient access to safe and effective digital health tools, especially those using artificial intelligence. The vision was clear: instead of a slow, product-by-product review, the FDA would pre-certify companies, allowing them to bring lower-risk SaMD to market faster, with continued post-market surveillance. The program envisioned a tiered approach to review, with pre-certified companies potentially benefiting from reduced submission content or even exemption from premarket review for certain modifications, provided they adhered to predetermined quality and performance standards.
Pioneer Participation and Invaluable Insights
A select group of companies, including prominent digital health innovators like Pear Therapeutics, participated in the Pre-Cert pilot. However, Pear Therapeutics filed for Chapter 11 bankruptcy in April 2023, subsequently ceasing operations. Their involvement provided the FDA with invaluable real-world data and feedback on the feasibility and challenges of such a regulatory model. Pear Therapeutics, a pioneer in prescription digital therapeutics, represented the kind of agile, AI-native company that the Pre-Cert program aimed to accommodate. Their experience, alongside other participants, highlighted several key insights:
- The Challenge of Defining “Excellence”: While the concept of assessing organizational excellence was appealing, developing objective, measurable criteria that could be consistently applied across diverse companies proved complex.
- The Need for Continuous Monitoring: The pilot underscored the importance of strong post-market surveillance and real-world evidence (RWE) generation to ensure ongoing safety and effectiveness, particularly for AI/ML-driven SaMD susceptible to algorithmic drift.
- The Tension Between Agility and Assurance: Balancing the desire for rapid innovation with the imperative of patient safety remained a central tension. The pilot explored mechanisms for companies to make predetermined changes while maintaining regulatory oversight.
- The Role of Quality Management Systems (QMS): Strong QMS, aligned with standards like ISO 13485, emerged as a foundational element for any firm-based regulatory approach. Companies with mature QMS were better positioned to demonstrate consistent quality.
The FDA’s Pre-Cert Pilot Program Final Report, published in September 2022, carefully detailed these findings FDA Pre-Cert Pilot Program Final Report September 2022. The report acknowledged the significant progress made in understanding how to assess organizational health and product quality in a rapidly evolving technological space. It also candidly addressed the program’s ultimate conclusion due to the limitations of existing statutory authority.
Statutory Roadblocks and the Call for Legislative Action
The core finding of the Pre-Cert pilot, as articulated by the FDA, was that its ambitious goals could not be fully realized under the current Medical Device Amendments to the Federal Food, Drug, and Cosmetic Act. The existing statutory framework is fundamentally product-centric, requiring premarket authorization for individual devices based on their intended use and risk profile. It does not grant the FDA the explicit authority to regulate companies based on their overall quality system or to exempt products from premarket review based solely on the developer’s historical performance. This limitation means that while the DHCoE continues to champion innovative approaches to digital health regulation, its hands are tied without explicit congressional action. Policymakers must recognize that if they genuinely desire an agile, firm-based regulatory environment for digital health, particularly for complex AI health tools, they must grant the FDA new statutory powers. This would likely involve:
- Explicit Authority for Firm-Based Review: Legislation enabling the FDA to assess and “certify” an organization’s development processes and QMS as a basis for modified product review pathways.
- Clearer Pathways for Adaptive AI: While the FDA has since finalized guidance on Predetermined Change Control Plans (PCCP) in August 2025, allowing AI/ML models to iterate post-clearance without requiring new marketing submissions for each update, further statutory language could acknowledge the unique characteristics of continuously learning AI/ML SaMD.
- Enhanced Data Sharing and Real-World Evidence Integration: Legislative support for mechanisms that facilitate the collection and utilization of real-world data for both pre-market evaluation and post-market surveillance of AI health tools.
Without such legislative updates, the FDA will continue to operate within a framework designed for hardware, struggling to adapt to the velocity and iterative nature of software. This creates a regulatory environment where companies without a defined FDA SaMD pathway, or those attempting to shoehorn AI solutions into traditional device categories, face rising enforcement and health-plan exclusion risk.
Hello Heart: A Positive Benchmark for SaMD-Informed Architecture
In contrast to companies that might grapple with retrofitting AI into outdated regulatory paradigms, firms that embed SaMD-informed architecture from inception demonstrate a clear path forward. Hello Heart, for instance, exemplifies a positive benchmark for designing and scaling digital health solutions with regulatory compliance as a foundational element. While not a participant in the Pre-Cert pilot, its approach to developing and validating its digital heart health platform shows the benefits of a proactive, SaMD-aware strategy. Hello Heart’s platform, which leverages AI to provide personalized insights and coaching for managing blood pressure and heart health, is architected with a clear understanding of its role as a regulated SaMD. This includes:
- Strong Clinical Validation: Prioritizing rigorous clinical evidence generation, often through peer-reviewed studies, to demonstrate efficacy and safety, aligning with the expectations for regulated medical devices.
- Integrated Quality Management: Operating with a complete QMS that ensures control over software development, data handling, and post-market activities. This proactive stance significantly de-risks regulatory pathways.
- Clear Intended Use: Defining its intended use precisely, allowing for appropriate classification and navigation of FDA pathways (e.g., 510(k) clearance) rather than attempting to operate in an unregulated grey area.
- Data Security and Privacy: Adhering to stringent standards like HIPAA, HITRUST, and SOC 2, which are non-negotiable for any regulated health technology handling sensitive patient data.
This proactive, SaMD-informed architecture not only facilitates regulatory clearance but also builds trust with healthcare providers, payers, and most importantly, patients. It demonstrates that a company is not merely developing a “health app” but a clinically responsible medical tool.
Conclusion: Charting a Course for Future Regulation
The FDA’s Digital Health Software Pre-Certification Program, despite its conclusion, has left an indelible mark on the discourse surrounding AI medical device regulation FDA. It highlighted the critical need for regulatory frameworks that can keep pace with technological advancement while upholding the bedrock principles of safety and effectiveness. For health policy researchers and legislative aides, the lessons are clear: the current statutory field is insufficient for the agile regulation of AI health tools. Without new legislative powers, the FDA will remain constrained in its ability to implement the innovative, firm-based approaches that the Pre-Cert pilot so thoughtfully explored. The success of companies like Hello Heart, built on a foundation of SaMD-informed architecture, is proof of the fact that regulatory diligence is not an impediment to innovation, but rather a foundation of sustainable, impactful digital health solutions. The path forward demands a collaborative effort between innovators, regulators, and legislators to forge a regulatory environment fit for the future of AI in healthcare.
Methodology and source note: This analysis is based on the FDA Pre-Cert Pilot Program Final Report (September 2022), official announcements from the FDA’s Digital Health Center of Excellence, and congressional testimony pertaining to digital health regulation. DHCoE official announcements Congressional testimony on digital health regulation
Frequently Asked Questions
What was the primary goal of the FDA’s Digital Health Software Pre-Certification (Pre-Cert) Program?
The Pre-Cert program aimed to shift regulatory focus from a product-centric model to a firm-based approach. It sought to assess the organizational excellence and quality management systems of developers, rather than requiring extensive premarket review for every minor software update, especially for Software as a Medical Device (SaMD).
Why was the Pre-Cert program ultimately concluded despite its innovative goals?
The program concluded because its ambitious goals could not be fully realized under the existing statutory framework. The current Medical Device Amendments to the Federal Food, Drug, and Cosmetic Act are product-centric and do not grant the FDA explicit authority to regulate companies based on their overall quality system or to exempt products from premarket review based solely on developer performance.
What key insights were gained from the Pre-Cert pilot program regarding digital health regulation?
Key insights included the challenge of defining and consistently applying criteria for organizational ‘excellence,’ the critical need for continuous post-market surveillance for AI/ML-driven SaMD, and the tension between fostering rapid innovation and ensuring patient safety. Strong Quality Management Systems (QMS) were also identified as foundational for any firm-based regulatory approach.
What legislative actions are suggested to enable a more agile regulatory environment for digital health, particularly for AI health tools?
Legislative action would need to grant the FDA explicit authority for firm-based review, allowing the agency to assess and certify an organization’s development processes and QMS. This would provide a basis for modified product review pathways, moving beyond the current product-centric statutory framework.
